The mechanism of action of Ruxolitinib tablets

Ruxolitinib is a kinase inhibitor that inhibits Janus-associated kinases (JAKs) JAK1 and JAK2. These two kinases mediate signaling of many cytokines and growth factors and are important for hematopoiesis and immune function. JAK signaling involves the recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus, resulting in the regulation of gene expression.

MF and PV are myeloproliferative neoplasms (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. In a mouse model of JAK2V617F-positive MPN, oral administration of ruxolitinib tablets prevented splenomegaly, preferentially reduced JAK2V617F mutant cells in the spleen, and reduced circulating inflammatory cytokines (such as TNF-α, IL-6). The JAK-STAT signaling pathway plays a role in regulating the development, proliferation, and activation of several immune cell types important in the pathogenesis of GVHD. In a mouse model of aGVHD, oral administration of ruxolitinib tablets was associated with reduced expression of inflammatory cytokines in colon homogenates and reduced immune cell infiltration in the colon.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.